In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MacroPore Biosurgery Inc.

Division of Royal DSM NV

Latest From MacroPore Biosurgery Inc.

Inion: Making Orthopedic Implants Fade Away

This Finnish company recently went public with a strategy built on bioabsorbable orthopedic devices with the goal of eventually making them bioactive as well.

Medical Device Strategy

After Drug-Eluting Stents: Making the Heart Smaller and the Market Larger

According to a recent report by Windhover/Medtech Insight, "Emerging US Markets for Myocardial Revascularization, Repair, and Regeneration Products and Technologies," drug-eluting stents achieved sales of $1.2 billion in 2003, and sales are expected to continue to grow at a compound annual rate of 27.5% to $4.1 billion in 2008. But revascularization technologies are only one category that offer grwoth opportunities for medtech companies. Another group of players hopes to address patients trending towards heart failure, as a result of heart scar formation or the death of heart muscle cells following a heart attack. New devices and device-enabled products have the potential to intervene in both of these structural processes in ways that existing heart failure drugs, which are merely palliative, can't. Medtech estimates that two strategies-cell therapies for heart muscle regeneration and remodeling devices for the heart--will serve a market that could grow to almost $190 million by 2008.

BioPharmaceutical Medical Device

StemSource Migrates to the Device World

A rudimentary orthobiologic rationale forms the basis of Macropore Biosurgery's acquisition of StemSource. Macropore wants to develop the devices needed to collect adipose stem cells (StemSource's technology) in the operating room for surgeons to administer them to help rebuild damaged organs and tissue. While financially modest, the deal is one of the first forays to bring the medical device and cell therapy worlds closer.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Royal DSM NV
  • Senior Management
  • Contact Info
  • MacroPore Biosurgery Inc.
    Phone: (858) 458-0900
    3020 Callan Road
    San Diego, CA 92121